Chronic Lymphocytic Leukaemia

Claire Dearden, Royal Marsden NHS Foundation Trust, Sutton, UK

Published online: January 2013

DOI: 10.1002/9780470015902.a0002173.pub3

Chronic lymphocytic leukaemia (CLL) results from the expansion of a clone of CD5+ B lymphocytes with distinct morphology and membrane antigens. The clinical course is variable and is determined by the stage of the disease. A number of serum, immunological and genetic markers are important determinants of prognosis. Treatment is only indicated in symptomatic patients with active disease. Initial therapy for fit patients is usually with combination chemoimmunotherapy, whereas single alkylating agents continue to be used for those unable to tolerate more intensive treatments. The presence of TP53 deletion, detected by fluorescence in situ hybridisation (FISH) analysis, predicts for poor response to conventional treatments and should be assessed in all patients before initiating therapy so that an alternative regimen can be selected. A number of new agents have shown activity in CLL.

Key Concepts:

  • CLL results from an expansion of clonal CD5+ CD19+ Blymphocytes with a unique diagnostic immunophenotype.
  • The clinical course of CLL is highly variable with some patients surviving decades without treatment, whereas others may die within 3–5 years of diagnosis.
  • Clinical stage and new laboratory markers give prognostic information. Patients whose CLL cells harbour TP53 deletions or mutations have a particularly poor outcome.
  • Patients with early stage asymptomatic disease do not require treatment.
  • Combination chemoimmunotherapy is recommended for fit patients with no TP53 abnormality.
  • Single agent alkylator therapy (chlorambucil or bendamustine) is suitable for less fit patients.
  • A number of newer agents are now available for management of relapsed/refractory patients.
  • Where possible patients should be treated within a clinical trial.
  • Allogeneic transplantation should be considered for younger fit patients with high-risk disease.
  • Care in the prevention and management of infections is crucial.

Keywords: B lymphocytes; lymphocytic leukaemia; lymphocytosis; lymphoma; prolymphocytes; splenectomy; clinical stage; doubling time; FISH

Figure 1. Blood film from a patient with chronic lymphocytic leukaemia, showing typical small lymphocytes.
Figure 2. Blood film from a patient with chronic lymphocytic leukaemia with more than 10% prolymphocytes (CLL-PL), showing the coexistence of four small lymphocytes and four prolymphocytes (larger and nucleolated).
Figure 3. FISH analysis with a centromeric probe for chromosome 12 showing three green dots (trisomy 12) in all the cells, and with a probe for 13q14 (two red dots) showing deletion (one red dot) in most cells with trisomy 12.
close
 References
    Bennett JM, Catovsky D, Daniel M-T et al. (1989) The French–American–British (FAB) cooperative group. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. Journal of Clinical Pathology 42: 567–584.
    Binet JL, Anquier A, Dighiero G et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–206.
    Bosch F, Abrisqueta P, Villamor N et al. (2009) Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Journal of Clincal Oncology 27: 4578–4584.
    Byrd JC, Peterson B, Morrison VA et al. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6–14.
    Catovsky D, Else M and Richards S (2011) Chlorambucil – Still not bad: a reappraisal. Clinical Lymphoma Myeloma and Leukemia 11: S2–S6.
    Catovsky D, Fooks J and Richards S (1989) For the Medical Research Council Working Party in Leukaemia in adults prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. British Journal of Haematology 72: 141–149.
    Catovsky D, Richards S, Matutes E et al. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chroniclymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370: 230–239.
    Chiorazzi N, Rai KR and Ferrarini M (2005) Chronic lymphocytic leukemia. New England Journal of Medicine 352(8): 804–815.
    Coad JE, Matutes E and Catovsky D (1993) Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature. Leukemia and Lymphoma 10: 245–264.
    Crespo M, Bosch F, VilIamor N et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine 348: 1764–1775.
    Damle RN, Wasil T, Fais F et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840–1847.
    Dohner H, Stilgenbauer S, Benner A et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine 343: 1910–1916.
    Dreger P, Corradini P, Kimby E et al. (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21: 12–17.
    Eichhorst BF, Busch R, Hopfinger G et al. (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukaemia. Blood 107(3): 885–891.
    Eichhorst BF, Busch R, Stilgenbauer S et al. (2009) First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114: 3382–3391.
    Ferrajoli A, Lee BN, Schlette EJ et al. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111: 5291–5297.
    Fischer K, Cramer P, Busch R et al. (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 30: 3209–3216.
    Gonzalez D, Martinez P, Wade R et al. (2011) Mutational status of the TP53gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. Journal of Clinical Oncology 29: 2223–2229.
    Hallek M, Cheson BD, Catovsky D et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446–5456.
    Hallek M, Fischer K, Fingerle-Rowson G et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164–1174.
    Hamblin TJ (2006) Autoimmune complications of chronic lymphocytic leukaemia. Seminars in Oncology 33(2): 230–239. Review.
    Hamblin TJ, Davis Z, Gardiner A et al. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848–1854.
    Hillmen P, Gribben J, Follows G et al. (2010) Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study. Blood 116, abstract 697.
    Hillmen P, Skotnicki AB, Robak T et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 25: 5616–5623.
    International Workshop on CLL (1981) Chronic lymphocytic leukaemia. Proposals for a revised prognostic staging system. British Journal of Haematology 48: 365–367.
    Keating MJ, O'Brien S, Albitar M et al. (2005) Early results of a chemo-immunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukaemia. Journal of Clinical Oncology 23(18): 4079–4088.
    Keating MJ, O'Brien S, Kantarjian H et al. (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81: 2878–2884.
    Keating MJ, Flinn I, Jain V et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554–3561.
    Knauf WU, Lissichkov T, Aldaoud A et al. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 27: 4378–4384.
    Leporrier M, Chevret S, Cazin B et al. (2001) Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98: 2319–2325.
    Lundin J, Kimby E, Bjorkholm M et al. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768–773.
    Matutes E, Owusu-Ankomah K, Morilla R et al. (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8: 1640–1645.
    Moreau EJ, Matutes E, A'Hern RP et al. (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). American Journal of Clinical Pathology 108: 378–382.
    Moreton P, Kennedy B, Lucas G et al. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukaemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 23(13): 2971–2979.
    Navarro B, García-Marco JA, Jones D, Price CM and Catovsky D (1998) Association and clonal distribution of trisomy 12 and 13q14 deletions in chronic lymphocytic leukaemia. British Journal of Haematology 102: 1330–1334.
    Oscier D, Wade R, Davis Z et al. (2010) Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 95: 1705–1712.
    Pettitt A, Jackson R, Carruthers S et al. (2012) Alemtuzumab in combination with methylprednisolone is a highly effevtive induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53; Final results of the National Cancer Research Institute CLL206 Trial. Journal of Clinical Oncology 30: 1647–1655.
    Rai KR, Peterson BL, Appelbaum FR et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine 343(24): 1750–1757.
    Rai KR, Sawitsky A, Cronkite ER et al. (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234.
    Robak T, Dmoszynska A, Solal-Céligny P et al. (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 28(10): 1756–1765.
    Stilgenbauer S, Zenz T, Winkler D et al. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 27: 3994–4001.
    Tam CS, O'Brien S, Wierda W et al. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975–980.
    Wierda WG, Kipps TJ, Mayer J et al. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 28: 1749–1755.
    Woyach JA, Ruppert AS, Heerema NA et al. (2011) Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. Journal of Clinical Oncology 29: 1349–1355.
 Further Reading
    Dighiero G, Maloum K, Desablens B et al. (1998) Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. New England Journal of Medicine 338: 1506–l514.
    Michallet M, Thiebaut A, Dreger P et al. (2000) Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). British Journal of Haematology 108: 595–601.
    Oscier D, Dearden C, Erem E et al. (2012) Guideline on the diagnosis, investigation and management of Chronic Lymphocytic Leukaemia. British Committee for Standards in Haematology. British Journal of Haematology 159(5): 541–564.
    book Swerdlow SH, Campo E and Harris NL et al. (eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol. 2, 127 pp. Lyon: IARC.

Related Sub-Topics:

Cells of the Immune System | Tumour Immunology | Cell Biology of Cancer
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Chronic Lymphocytic Leukaemia
 
How to Cite close
Dearden, Claire(Jan 2013) Chronic Lymphocytic Leukaemia. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0002173.pub3]